These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 35585358)

  • 1. Prospective analysis of the expression status of FGFR2 and HER2 in colorectal and gastric cancer populations: DS-Screen Study.
    Yasui H; Takeno A; Hara H; Imamura H; Akamatsu H; Fujitani K; Nakane M; Kondoh CN; Yukisawa S; Nasu J; Miyata Y; Makiyama A; Ishida H; Yoshida N; Matsumura E; Ishigami M; Sugihara M; Ochiai A; Doi T
    Int J Colorectal Dis; 2022 Jun; 37(6):1393-1402. PubMed ID: 35585358
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Establishment of patient-derived gastric cancer xenografts: a useful tool for preclinical evaluation of targeted therapies involving alterations in HER-2, MET and FGFR2 signaling pathways.
    Wang H; Lu J; Tang J; Chen S; He K; Jiang X; Jiang W; Teng L
    BMC Cancer; 2017 Mar; 17(1):191. PubMed ID: 28292264
    [TBL] [Abstract][Full Text] [Related]  

  • 3. HER2, MET and FGFR2 oncogenic driver alterations define distinct molecular segments for targeted therapies in gastric carcinoma.
    Liu YJ; Shen D; Yin X; Gavine P; Zhang T; Su X; Zhan P; Xu Y; Lv J; Qian J; Liu C; Sun Y; Qian Z; Zhang J; Gu Y; Ni X
    Br J Cancer; 2014 Mar; 110(5):1169-78. PubMed ID: 24518603
    [TBL] [Abstract][Full Text] [Related]  

  • 4. DEAD-Box Protein RNA-Helicase DDX6 Regulates the Expression of HER2 and FGFR2 at the Post-Transcriptional Step in Gastric Cancer Cells.
    Tajirika T; Tokumaru Y; Taniguchi K; Sugito N; Matsuhashi N; Futamura M; Yanagihara K; Akao Y; Yoshida K
    Int J Mol Sci; 2018 Jul; 19(7):. PubMed ID: 29987267
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mutually exclusive FGFR2, HER2, and KRAS gene amplifications in gastric cancer revealed by multicolour FISH.
    Das K; Gunasegaran B; Tan IB; Deng N; Lim KH; Tan P
    Cancer Lett; 2014 Oct; 353(2):167-75. PubMed ID: 25086186
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Expression profiles of HER2, EGFR, MET and FGFR2 in a large cohort of patients with gastric adenocarcinoma.
    Nagatsuma AK; Aizawa M; Kuwata T; Doi T; Ohtsu A; Fujii H; Ochiai A
    Gastric Cancer; 2015 Apr; 18(2):227-38. PubMed ID: 24626858
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cancer-related FGFR2 overexpression and gene amplification in Japanese patients with gastric cancer.
    Minashi K; Yamada T; Hosaka H; Amagai K; Shimizu Y; Kiyozaki H; Sato M; Soeda A; Endo S; Ishida H; Kamoshida T; Sakai Y; Shitara K
    Jpn J Clin Oncol; 2021 Oct; 51(10):1523-1533. PubMed ID: 34258618
    [TBL] [Abstract][Full Text] [Related]  

  • 8. FGFR2 amplification has prognostic significance in gastric cancer: results from a large international multicentre study.
    Su X; Zhan P; Gavine PR; Morgan S; Womack C; Ni X; Shen D; Bang YJ; Im SA; Ho Kim W; Jung EJ; Grabsch HI; Kilgour E
    Br J Cancer; 2014 Feb; 110(4):967-75. PubMed ID: 24457912
    [TBL] [Abstract][Full Text] [Related]  

  • 9. FGFR2, HER2 and cMet in gastric adenocarcinoma: detection, prognostic significance and assessment of downstream pathway activation.
    Betts G; Valentine H; Pritchard S; Swindell R; Williams V; Morgan S; Griffiths EA; Welch I; West C; Womack C
    Virchows Arch; 2014 Feb; 464(2):145-56. PubMed ID: 24306956
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evaluation of Fibroblast Growth Factor Receptor 2 Expression, Heterogeneity and Clinical Significance in Gastric Cancer.
    Han N; Kim MA; Lee HS; Kim WH
    Pathobiology; 2015; 82(6):269-79. PubMed ID: 26516773
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinicopathological factors associated with HER2 status in gastric cancer: results from a prospective multicenter observational cohort study in a Japanese population (JFMC44-1101).
    Matsusaka S; Nashimoto A; Nishikawa K; Miki A; Miwa H; Yamaguchi K; Yoshikawa T; Ochiai A; Morita S; Sano T; Kodera Y; Kakeji Y; Sakamoto J; Saji S; Yoshida K
    Gastric Cancer; 2016 Jul; 19(3):839-51. PubMed ID: 26265390
    [TBL] [Abstract][Full Text] [Related]  

  • 12. FGF18-FGFR2 signaling triggers the activation of c-Jun-YAP1 axis to promote carcinogenesis in a subgroup of gastric cancer patients and indicates translational potential.
    Zhang J; Wong CC; Leung KT; Wu F; Zhou Y; Tong JHM; Chan RCK; Li H; Wang Y; Yan H; Liu L; Wu WKK; Chan MWY; Cheng ASL; Yu J; Wong N; Lo KW; To KF; Kang W
    Oncogene; 2020 Oct; 39(43):6647-6663. PubMed ID: 32934314
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Correlation of human epidermal growth factor receptor 2 expression with clinicopathological characteristics and prognosis in gastric cancer.
    He C; Bian XY; Ni XZ; Shen DP; Shen YY; Liu H; Shen ZY; Liu Q
    World J Gastroenterol; 2013; 19(14):2171-8. PubMed ID: 23599643
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The beginning of the era of precision medicine for gastric cancer with fibroblast growth factor receptor 2 aberration.
    Ooki A; Yamaguchi K
    Gastric Cancer; 2021 Nov; 24(6):1169-1183. PubMed ID: 34398359
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Multiple receptor tyrosine kinase activation attenuates therapeutic efficacy of the fibroblast growth factor receptor 2 inhibitor AZD4547 in FGFR2 amplified gastric cancer.
    Chang J; Wang S; Zhang Z; Liu X; Wu Z; Geng R; Ge X; Dai C; Liu R; Zhang Q; Li W; Li J
    Oncotarget; 2015 Feb; 6(4):2009-22. PubMed ID: 25576915
    [TBL] [Abstract][Full Text] [Related]  

  • 16. miR‑494 inhibits cancer‑initiating cell phenotypes and reverses resistance to lapatinib by downregulating FGFR2 in HER2‑positive gastric cancer.
    Yu Y; Yu X; Liu H; Song Q; Yang Y
    Int J Mol Med; 2018 Aug; 42(2):998-1007. PubMed ID: 29786108
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Intra-tumoral FGFR2 Expression Predicts Prognosis and Chemotherapy Response in Advanced HER2-positive Gastric Cancer Patients.
    Nakamura N; Kaida D; Tomita Y; Miyata T; Miyashita T; Fujita H; Kinami S; Ueda N; Takamura H
    Cancer Diagn Progn; 2022; 2(3):293-299. PubMed ID: 35530644
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tumor-Associated Fibroblasts Promote HER2-Targeted Therapy Resistance through FGFR2 Activation.
    Fernández-Nogueira P; Mancino M; Fuster G; López-Plana A; Jauregui P; Almendro V; Enreig E; Menéndez S; Rojo F; Noguera-Castells A; Bill A; Gaither LA; Serrano L; Recalde-Percaz L; Moragas N; Alonso R; Ametller E; Rovira A; Lluch A; Albanell J; Gascon P; Bragado P
    Clin Cancer Res; 2020 Mar; 26(6):1432-1448. PubMed ID: 31699826
    [TBL] [Abstract][Full Text] [Related]  

  • 19. In situ analysis of FGFR2 mRNA and comparison with FGFR2 gene copy number by dual-color in situ hybridization in a large cohort of gastric cancer patients.
    Kuboki Y; Schatz CA; Koechert K; Schubert S; Feng J; Wittemer-Rump S; Ziegelbauer K; Krahn T; Nagatsuma AK; Ochiai A
    Gastric Cancer; 2018 May; 21(3):401-412. PubMed ID: 28852882
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prognostic impact of HER2, EGFR, and c-MET status on overall survival of advanced gastric cancer patients.
    Fuse N; Kuboki Y; Kuwata T; Nishina T; Kadowaki S; Shinozaki E; Machida N; Yuki S; Ooki A; Kajiura S; Kimura T; Yamanaka T; Shitara K; Nagatsuma AK; Yoshino T; Ochiai A; Ohtsu A
    Gastric Cancer; 2016 Jan; 19(1):183-91. PubMed ID: 25682441
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.